Numerous coronavirus vaccine development programmes are currently being run at a fast pace, with some promising candidates going into phase 1 (dosage and absence of toxicity), some advancing into phase 2 (efficacy on small groups of individuals), and some arguably with the potential to move into phase 3 before the summer (use across groups of thousands of patients, across multiple countries).
Image: Equipment at a British lab working on a potential vaccine for COVID-19. Image: Reuters/Carl Recine
